MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/tau-2025-1-912

Медицинская библиотека · Translational andrology and urology · 2026

Development and validation of an MRI radiomics-based model for predicting progression risk in prostate cancer after endocrine therapy.

Ding Ke, Chen Qiong, Huang Lifeng, Huang Ruisui, Liu Manrong, Gong Mofeng, Huang Haibo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Prostate cancer often progresses to castration-resistant disease despite initial response to endocrine therapy, necessitating better predictive tools like magnetic resonance imaging (MRI) radiomics. This study aimed to develop a predictive model using MRI radiomics and clinicopathological factors to assess tumor progression risk after endocrine therapy in prostate cancer patients, and to create a nomogram for evaluating progression-free survival (PFS).

METHODS

A total of 136 prostate cancer patients receiving endocrine therapy were retrospectively analyzed and randomly split into training (n=95) and internal validation (n=41) sets (7:3). A radiomics-clinical nomogram was developed and validated internally and externally (n=52). Performance was assessed for discrimination, calibration, and clinical utility.

RESULTS

Independent predictors for tumor progression included time to prostate-specific antigen (PSA) nadir, Gleason score, tumor T stage, and bone metastasis. The combined prediction model achieved C-index values of 0.884, 0.839, and 0.795 in training, internal validation, and external validation sets, respectively. Calibration curves indicated accuracy; decision curve analysis confirmed clinical utility. Kaplan-Meier analysis showed that using a nomogram score of 79.44 as the cutoff effectively stratified prostate cancer patients into high-risk (>79.44) and low-risk (≤79.44) groups, with significantly shorter PFS in the high-risk group (log-rank test, P<0.001).

CONCLUSIONS

The model incorporating MRI radiomics features with clinicopathological factors effectively predicts progression risk post-endocrine therapy in prostate cancer patients, aiding personalized clinical decisions to improve prognosis.

Для цитирования: Ding Ke, Chen Qiong, Huang Lifeng, Huang Ruisui, Liu Manrong, Gong Mofeng, Huang Haibo. Development and validation of an MRI radiomics-based model for predicting progression risk in prostate cancer after endocrine therapy.. Translational andrology and urology. 2026. DOI: 10.21037/tau-2025-1-912.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.